Asian Journal of Transfusion Science

LETTER TO THE EDITOR
Year
: 2011  |  Volume : 5  |  Issue : 2  |  Page : 178--179

YMDD motif mutation after lamivudine therapy


Seyed Mohammad Jazayeri1, Seyed Mohammad Miri2, Seyed Moayed Alavian2,  
1 Hepatitis B Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Tehran, Iran

Correspondence Address:
Seyed Mohammad Miri
P.O. Box 14155/3651, Tehran
Iran




How to cite this article:
Jazayeri SM, Miri SM, Alavian SM. YMDD motif mutation after lamivudine therapy.Asian J Transfus Sci 2011;5:178-179


How to cite this URL:
Jazayeri SM, Miri SM, Alavian SM. YMDD motif mutation after lamivudine therapy. Asian J Transfus Sci [serial online] 2011 [cited 2022 Jul 5 ];5:178-179
Available from: https://www.ajts.org/text.asp?2011/5/2/178/83252


Full Text

Sir,

We have read the article entitled "Probing rate of YMDD motif mutant in lamivudine treatment of Iranian patients with chronic hepatitis B virus infection" by Ghandehari et al. [1] There are some points that seem to be helpful.

Hepatitis B virus (HBV) infection is the main cause of liver disease in our region and Isfahan (Central of Iran) is low endemicity for HBV infection. [2] The most of HBV infected in Iran are HBeAg negative, [3] but in Ghandehari et al.'s work the most cases (76%) were HBeAg positive.

In the Materials and Method section, the authors did not refer to the trade characteristics of ELISA kit. Published data indicated that not all ELISA tests could find HBsAg in chronic patients due to either HBsAg mutants [4] or very low levels of HBV DNA. [5] Also, in the Results section they did not differentiate between serology and DNA detection, and no tables were included in the results, thus discriminating this correlation seems to be impossible for the readers.

What was the aim of study? If the goal was finding the YMDD mutations in the patients who received lamivudine, where were the clinical criteria (histology, serology and biochemistry) for differentiating between patients who contained the mutations and those who did not? This paper does not allocate molecular finding to the above clinical points of view. Finding YMDD in 12% or 14% of patients while they were PCR and HBsAg negative indicated that the methodology used by the authors was inaccurate, although the selection bias of the patient studies could not be ruled out. Further, published and unpublished data from Iran indicated a higher rate of drug resistance among patients after 48 weeks of antiviral therapy. [6] Taken together, the authors should have used other more sensitive serologic and molecular approaches.

In the Discussion section, the authors concluded that a significant difference existed between YMDD mutation and lamivudine therapy. What does this mean? As mentioned above, the authors did not differentiate between these two groups of patients. Thus, how did they make this conclusion?

There are also some mistakes in the abstract, as YMDD results were included in the Conclusion section of the Abstract. Also, there are two different percentages (12% and 14%) for the rate of these mutations in the patients.

References

1Ghandehari F, Pourazar A, Zadeh MS, Tajedin N. Probing rate of YMDD motif mutant in lamivudine treatment of Iranian patients with chronic hepatitis B virus infection. Asian J Transfus Sci 2011;5:32-4.
2Nokhodian Z, Kassaian N, Ataei B, Javadi AA, Shoaei P, Farajzadegan Z, et al. Hepatitis B Markers in Isfahan, Central Iran: A Population-Based Study. Hepat Mon 2009;9:12-6.
3Jazayeri S, Carman W. Evolution of Hepatitis B Genotype D in the Middle East and South Asia. Hepat Mon 2009;9:9-111.
4Kreutz C. Molecular, immunological and clinical properties of mutated hepatitis B viruses. J Cell Mol Med 2002;6:113-43.
5Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology 2001;34:194-203.
6Ravanshad M, Sabahi F, Falahi S, Kenarkoohi A, Amini-Bavil-Olaee S, Hosseini SY, et al. Prediction of hepatitis B virus lamivudine resistance based on YMDD. Hepat Med 2011;11:108-13.